Linear Minerals Drills 1.00 Percent Lithium Oxide over 8.90 meters at Augustus
LC24-97 Highlights
The mineralization in four lithium zones is distributed in mixed lithologies of pegmatites with spodumene as main lithium mineral, as well as in the basement rocks with Holmquistite being the main lithium minerals. This hole was placed about 40 m step out from drill hole LC21-20 and was aimed at increasing the footprint of the main Augustus mineralized zone.
Four Lithium Intercepts:
3.35 m at 0.82% Li2O from 10.15 m depth, with 714 ppm Cs and 1,550 ppm Rb.
4.25 m at 1.19% Li2O from 89.4 m depth, with 215 ppm Be, 61 ppm Ga, 369 ppm Rb, 79 ppm Nb, and 179 ppm Ta.
10 m at 0.67% Li2O from 97.4 m drilled depth, with 451 ppm Be, 1,206 ppm Cs, 57 ppm Ga, 4,178 ppm Rb, 49 ppm Nb, and 72 ppm Ta.
8.90 m at 1% Li2O from 139 m depth, with 288 ppm Be, 560 ppm Cs, 88 ppm Ga, 3,947 ppm Rb, 73 ppm Nb, and 87 ppm Ta.
Drill Program Details:
Drill hole LC23-97 was drilled at location 5367785.908N, 287015.498E, UTM NAD 1983 Zone 18N, at azimuth 28.31 degrees (true north) and dip -50 with a drilled depth of 161 m. The drill hole was placed at the main Augustus zone.
The drill program was designed based on historical and current exploration data. Drilling was conducted by Forage Pelletier Drilling of Chapais, Quebec, and core logging and sampling took place at a core shack in St-Dominique du Rosaire, approximately 50 km from the property. The 2024 drill program included 11 drill holes, totaling 1,558 metres. To date, a total of 100 drill holes have been completed on the Property, with a cumulative diamond drilling of 18,165.64 metres.
Drill core was sampled using a rock saw. For quality control and assurance (QA/QC), field duplicates, standards, and blanks were inserted at industry-standard intervals. Samples were bagged and tagged using best practices before delivered to AGAT Laboratories in Val-d'Or, QC, for analysis. AGAT performed Sodium Peroxide Fusion with ICP-OES and ICP-MS Finish (Code 201-378). AGAT is an independent, accredited laboratory with ISO certification for certain tests. All intersections reported are based on drilled width and have not been converted to the true width.
Qualified Person:
Afzaal Pirzada, P.Geo., an independent geological consultant of the Company, and a 'Qualified Person' for the purposes of National Instrument 43-101 - Standards of Disclosure for Mineral Projects , has reviewed and approved the scientific and technical information contained in this news release.
About the Augustus Lithium Property
The Company owns 100% of an interest in the Augustus Property located in Landrienne and Lacorne-Townships, Quebec, Canada. The Property covers a total area of over 15,000 hectares, approximately 40 kilometres northwest of the town of Val d'Or. To date, 100 diamond drill holes totaling 18,165.64 metres have been completed on the Property.
ON BEHALF OF THE BOARD OF
Linear Minerals Corp.
'Gurminder Sangha'
Gurminder Sangha
CEO & Director
Neither the Canadian Securities Exchange (CSE) nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release and has neither approved nor disapproved the contents of this news release.
Forward-looking Information
This news release contains forward-looking information within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding the Company's exploration plans, potential mineralization, and future activities. While the Company believes the assumptions underlying such information are reasonable, actual results may vary, and undue reliance should not be placed on forward-looking statements.
Table 1: Drill Hole LC24-97 Assay Highlights
Lab Sample ID
Field Sample ID
Depth From (m)
Depth To (m)
Total Width (m)
Analyte:
Be
Cr
Cs
Fe
Ga
Li
Li2O
Nb
Ni
Rb
Ta
Unit:
ppm
%
ppm
%
ppm
ppm
%
ppm
ppm
ppm
ppm
RDL:
20
0.002
0
0.01
0.5
10
5
10
2
0.5
6372332
1157604
10.15
11.15
1
Holmquistite
<20
0.022
279
5.49
21.4
5,120
1.10
12
127
690
3.1
6372333
1157605
11.15
12.05
0.9
Holmquistite
22
0.016
249
4.45
20.4
5,330
1.15
9
93
598
1.1
6372334
1157606
12.05
12.6
0.55
Chlorite schist
<20
0.065
1,730
7.47
24.8
1,920
0.41
13
368
3,260
6.1
6372335
1157607
12.6
13.5
0.9
Holmquistite
28
0.035
599
5.61
27.1
2,940
0.63
10
195
1,650
3.2
First Lithium Intercept
10.15
13.5
3.35
25
0
714
6
23
3,828
0.82
11
196
1,550
3
6372336
1157608
13.5
14.35
0.85
Pegmatite
329
0.003
17
0.58
48.8
110
0.02
63
10
108
82.9
6372337
1157609
14.35
15.35
1
Country Rock
62
0.221
1,190
6.68
21.7
1,500
0.32
14
635
2,170
11.6
6372339
1157611
34.15
35.15
1
Country Rock
162
0.193
283
5.4
30.9
448
0.10
23
1470
1,210
28.6
6372340
1157612
35.15
36.15
1
Pegmatite
421
0.006
96
0.78
63.5
1,380
0.30
90
27
684
108
6372341
1157613
36.15
37.15
1
Pegmatite
84
0.002
27
0.48
53
147
0.03
114
<10
307
162
6372342
1157614
37.15
37.85
0.7
Pegmatite
395
0.002
30
0.45
47.8
149
0.03
140
<10
160
192
6372343
1157615
37.85
38.85
1
Meta Basalt
22
0.216
272
5.67
26.6
589
0.13
11
1740
980
5.8
6372344
1157616
85.85
86.85
1
Country Rock
<20
0.353
23
6.95
10.2
60
0.01
7
1800
48
<0.5
6372345
1157617
86.85
87.85
1
Country Rock
98
0.289
1,320
5.91
19.6
799
0.17
7
1540
3,380
21.5
6372346
1157618
87.85
88.85
1
Country Rock
29
0.169
1,360
5.22
26.4
1,140
0.25
6
1400
3,720
7.3
Anomalous Ni-Cr Zone
85.85
88.85
3
0.26
744
6
21
647
0.14
8
1620
2,032
12
6372347
1157619
88.85
89.4
0.55
Pegmatite
165
0.003
26
0.54
34.1
644
0.14
57
<10
360
77.2
6372349
1157621
89.4
90.5
1.1
Pegmatite
337
0.003
44
0.61
64.9
5,130
1.10
113
<10
368
301
6372350
1157622
90.5
91.5
1
Pegmatite
175
0.002
30
0.56
66.2
5,510
1.19
69
<10
412
143
6372351
1157623
91.5
92.55
1.05
Pegmatite
200
0.003
28
0.56
67.3
6,520
1.40
93
<10
271
187
6372352
1157624
92.55
93.65
1.1
Pegmatite
148
0.003
68
0.56
46.4
4,950
1.07
42
<10
426
84.6
Second Lithium Intercept
89.40
93.65
4.25
215
0.003
43
1
61
5,528
1.19
79
<10
369
179
6372353
1157625
93.65
94.75
1.1
Schist
<20
0.18
284
6.03
20
239
0.05
9
1,750
741
23.1
6372354
1157626
94.75
95.75
1
Schist
<20
0.167
12
6.19
9.7
55
0.01
6
1,760
10
<0.5
6372355
1157627
95.75
96.75
1
Schist
<20
0.144
13
5.86
7.9
51
0.01
9
1,630
10
<0.5
6372356
1157628
96.75
97.40
0.65
Schist
<20
0.144
4
5.32
6.8
54
0.01
<5
1,390
9
<0.5
Anomalous Ni-Cr Zone
93.65
97.40
3.75
0.16
1,633
6372357
1157629
97.40
98.10
0.7
Schist
102
0.101
2,530
4.39
42
1,630
0.35
17
914
6,990
50.7
6372359
1157631
98.10
99.00
0.9
Pegmatite
462
0.003
56
0.78
56.4
3,580
0.77
62
<10
472
97.6
6372360
1157632
99.00
100.00
1
Pegmatite
308
0.003
45
0.58
56
3,830
0.82
59
<10
589
122
6372361
1157633
100.00
100.40
0.4
Pegmatite
1270
0.003
96
0.4
56.9
616
0.13
39
<10
216
78
6372362
1157634
100.40
101.4
1
Schist
290
0.126
2,540
3.39
87.7
4,320
0.93
35
1480
9,530
48.9
6372363
1157635
101.40
102.4
1
Schist
317
0.115
3,330
4.08
76.4
4,270
0.92
25
986
9,930
27.1
6372364
1157636
103.80
104.8
1
Schist
156
0.096
1,840
4.56
50
3,550
0.76
26
948
7,610
28.4
6372365
1157637
104.80
105.6
0.8
Pegmatite
753
0.003
79
0.6
56.8
4,040
0.87
145
<10
383
142
6372366
1157638
105.60
106.4
0.8
Pegmatite
398
0.029
725
1.63
73.9
4,330
0.93
79
265
3,540
119
6372367
1157639
106.40
107.4
1
Schist
<20
0.192
818
5
17.2
738
0.16
6
1610
2,520
3.9
Third Lithium Intercept
97.40
107.4
10
451
0.07
1,206
3
57
3,090
0.67
49
4,178
72
6372369
1157641
138.00
139
1
Schist
<20
0.128
1,840
9.14
40.4
2,060
0.44
33
632
6,000
5.7
6372370
1157642
139.00
140.00
1
Schist
154
0.094
1,350
3.15
102
4,130
0.89
89
322
6,490
97.4
6372371
1157643
140.00
141.05
1.05
Schist
638
0.002
50
0.31
40.2
140
0.03
36
<10
117
43.2
6372372
1157644
141.05
142.1
1
Peg/schist
411
0.048
394
1.41
70.7
1,740
0.37
74
147
2,020
90.6
6372373
1157645
142.05
143
0.95
Peg/schist
262
0.026
227
0.92
77.5
3,820
0.82
80
70
1,740
108
6372374
1157646
143.00
143.9
0.85
Peg/schist
<20
0.15
1,220
3.09
121
6,960
1.50
98
497
9,380
69
6372375
1157647
143.85
144.50
0.65
Peg/schist
<20
0.058
803
1.89
125
5,450
1.17
96
203
7,450
127
6372376
1157648
144.50
145.20
0.7
Peg/schist
267
0.003
34
0.58
58.4
7,350
1.58
53
<10
176
110
6372377
1157649
145.20
145.95
0.75
Peg/schist
287
0.004
47
0.66
66
7,040
1.52
37
16
353
69.3
6372379
1157651
145.95
147.00
1.05
Peg/schist
21
0.11
982
2.56
129
6,280
1.35
98
511
7,760
90.6
6372380
1157652
147.00
147.90
0.9
Peg/schist
267
0.034
498
1.44
94.8
3,670
0.79
65
180
3,980
68.9
Fourth Lithium Intercept
139.00
147.90
8.90
288
0.05
560
2
88
4,658
1.00
73
243
3,947
87
6372381
1157653
147.90
149.00
1.1
Peg/schist
333
0.003
50
0.39
57.5
333
0.07
50
<10
440
80.2
6372382
1157654
149.00
150.10
1.1
Peg/schist
456
0.002
53
0.46
55.4
2,490
0.54
60
<10
353
94.5
6372383
1157655
150.10
151.10
1
Schist
76
0.225
2,560
5.78
71.5
2,470
0.53
17
912
7,950
17.5
6372384
1157656
151.10
152.10
1
Country Rock
<20
0.273
1,050
5.94
23.3
865
0.19
<5
1320
3,250
<0.5
Note: A standard conversion factor of 2.15 was used to report Li to Li2O values
All intersections reported are based on drilled width and have not been converted to the true width.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
4 minutes ago
- Miami Herald
AI and Virtual Coaching Are Transforming Reemployment - Big Interview Shows What's Possible
NEW YORK CITY, NY / ACCESS Newswire / August 21, 2025 / As the White House releases its America's Talent Strategy: Building the Workforce for the Golden Age, state agencies are facing an urgent question: how to prepare workers for a job market being reshaped at unprecedented speed by AI and automation. The challenge is clear. By 2030, 14% of workers will need to change jobs due to AI and automation, and 80% of the workforce will see disruption to their daily tasks from large language models like ChatGPT (McKinsey). Reemployment programs, built for a pre-AI economy, are struggling to keep pace. The paradox is that the same technologies fueling disruption may also be the key to recovery. Across the country, workforce agencies are piloting AI-powered assessments, virtual reality training, and AI-driven interview coaching to move people back into work faster and with better job matches. "Over the last decade, I've watched hiring trends shift-but nothing compares to the pace of change we're seeing now," said Pamela Skillings, co-founder and chief coach at Big Interview. "AI isn't just changing what jobs exist, it's changing how quickly people need to adapt. Agencies that integrate these tools now will be the ones that keep their workers competitive." AI-enabled resume and interview tools-like those built into Big Interview-are helping states like Idaho provide personalized interview feedback to thousands of unemployed residents annually, without increasing staff workload. These same approaches are in line with the White House's America's Talent Strategy Pillar IV and V priorities: Accountability: Linking investments to clear employment outcomes, shortening unemployment, and redirecting resources to programs that prove & Innovation: Using AI-era tools to pilot new models, adapt training to labor market needs, and scale access to rural and underserved communities. For state agencies, the impact is measurable. Big Interview's AI-driven mock interview simulations and resume optimization tools have already supported over two million job seekers worldwide, helping them land jobs up to 5x faster than the national average. "When you can serve thousands of people with personalized interview feedback-without adding staff-you're not just innovating, you're solving real problems," said Steve Ruder, Vice President at Big Interview. "We've seen measurable results in multiple states, and the technology is proven to scale." As agencies evaluate their next steps under the America's Talent Strategy report, one priority stands out: evaluate and pilot AI-driven tools that can scale impact, measure results, and adapt quickly to changing labor market needs. Contact Information Steve Ruder Vice Presidentsteve@
Miami Herald
4 minutes ago
- Miami Herald
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Enrollment has reached approximately 25% in Jaguar's ongoing field study of Canalevia-CA1 in dogs SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is participating in the 2025 Animal Health Summit in support of the company's goal of securing a collaboration to expand the indication of Canalevia (crofelemer delayed-release tablets) from treatment of chemotherapy-induced diarrhea (CID) in dogs to treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) for treatment of CID in dogs. The Animal Health Summit, hosted by KC Animal Health Corridor, takes place August 25-26, 2025 in Kansas City, Missouri. "I'm pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of Canalevia for treatment of general diarrhea in dogs," said Lisa Conte, Jaguar's Founder and CEO. "Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs; obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs. Forging a partnership to support these goals is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for Jaguar this year." "Our goal is to be as comprehensive as possible in the search for the best partner for Canalevia - and with this goal in mind we look forward to participating in the 2025 Animal Health Summit. Our team is available for partnership discussions at the event," said David Sesin, PhD, Jaguar's Chief Manufacturing Officer. A report by the American Veterinary Medical Foundation concluded that there were approximately 90 million dogs in the U.S. in 2024, of which Jaguar estimates more than 11 million suffer from general diarrhea each year. Data from the European Pet Food Industry Federation concluded that there were approximately 104 million dogs in Europe in 2022. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the U.S. and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general diarrhea in dogs - both in the U.S. and the EU," said Conte. "We estimate that U.S. veterinarians see approximately four million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general diarrhea in the U.S. and/or globally." As announced, enrollment has begun in Jaguar's ongoing full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs. With multiple veterinary oncology clinics signed on to take part in this study, enrollment has reached 25%, and Jaguar is in discussions with other veterinary oncology clinics regarding possible participation. The objective of this ongoing, prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs - the fourth and final technical section required to support potential full FDA approval of the drug for dogs with CID. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected for the control group. Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics. "In the EU, as we announced, it may be possible to obtain approval of Canalevia for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea," Conte said. "While this completed trial did not meet its stated primary endpoint, the study results are clinically significant when analyzed using an alternate endpoint, defining treatment success as any dog that had no episodes of diarrhea following the first treatment with either Canalevia or placebo. Using this revised endpoint, the study data shows that dogs treated with Canalevia resolved their diarrhea within 24 hours of the first administration of the drug, with the data demonstrating statistical and clinical relevance compared to placebo-treated dogs." Jaguar plans to submit a dossier to the European Medicines Agency (EMA) to outline the results of the updated analysis of the company's completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application (MAA) for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs. Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy. About Conditional Approval and Full Approval Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA's conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the "substantial evidence" standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving "substantial evidence of effectiveness" for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug. About Chemotherapy-induced Diarrhea (CID) in Dogs According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.1 According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S. Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID. Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs. About Canalevia®-CA1 Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a "small number" threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use. About Crofelemer Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities. Important Safety Information About Canalevia®-CA1 For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that company personnel will attend the 2025 Animal Health Summit, Jaguar's expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in dogs with general diarrhea, Jaguar's expectation that it will submit a dossier to the EMA to outline the results of the updated analysis of the company's completed study of Canalevia in dogs with general diarrhea, Jaguar's expectation that, if the dossier is acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs to the EMA, and Jaguar's expectation that, if the application is approved by the EMA, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 1 "Cancer in Pets." American Veterinary Medical Association, 2021, 2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398 Source: Jaguar Health, Inc. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Yahoo
an hour ago
- Yahoo
BuildDirect.com Technologies Inc. Second Quarter 2025 Conference Call
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - Technologies Inc. (TSXV: BILD) (OTCQB: BDCTF) ("BuildDirect" or the "Company"), a leading omnichannel building material retailer, today announced that the Company will report its second quarter 2025 financial results before the market open on Thursday, August 28, 2025. Management will host a conference call and webcast to discuss the Company's financial results at 11:00 AM (PDT) / 2:00 PM (EDT) on Thursday, August 28, 2025. BuildDirect Second Quarter 2025 Financial Results Conference Call Date: Thursday, August 28, 2025Time: 11:00 AM (PDT) / 2:00 PM (EDT)Live Webinar: The Company will host a Q&A session during the webinar. The replay will be available approximately 24 hours after the completion of the live webinar on the Investor Relations section of BuildDirect's website at About BuildDirect: BuildDirect (TSXV: BILD) is a growing omnichannel building material retailer. BuildDirect connects North American home improvement B2B and B2C organizations, and homeowners with quality building materials and services through its robust global supply chain network. BuildDirect's growth trajectory, strong product offering, and proprietary heavyweight delivery network are delivering value today, solidifying its position as an innovative player in the home improvement industry. For more information, visit For further information: BuildDirect Investor Relationsir@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
